EU Policy Symposium Session 2
Policy & Regulatory Affairs Council
Tuesday, October 7, 15:00 – 16:30

Session Title
Growing Role of Health Technology Assessment (HTA) in Nuclear Medicine: Implications in Light of the New EU HTA Regulation

Chairpersons
Nadia Withofs (Liège, Belgium)
Jolanta Kunikowska (Warsaw, Poland)

Programme

15:00 – 15:05 Introduction by the Co-Chairs

15:05 – 15:10 **Setting the Stage: The Future of HTA in Nuclear Medicine**
Nadia Withofs, Liège University Hospital

15:10 – 15:25 **The EU Regulation on Health Technology Assessment (HTAR) applying from January 2025**
Julie Spony, Policy officer, European Commission, Directorate-General for Health and Food Safety, Unit C2 Health Technology Assessment (Belgium)

15:25 – 15:40 **The impact of EU HTAR on National HTA bodies: The Case of Belgium**
Mattias Neyt, Belgian Health Care Knowledge Centre (Belgium)

15:40 – 15:55 **Patient-Centred Perspectives: Implications for radioligand therapy in light of the new EU HTAR**
Erik Briers, Patient Representative, Europa Uomo (Belgium)

15:55 – 16:10 **Positioning imaging in the HTA process**
Minerva Becker, European Society of Radiology (Switzerland)

16:10 – 16:25 Open Forum
- Panel Discussion
- Q&A with the audience

16:25 – 16-30 Conclusions by the Co-Chairs
- Concluding remarks
- Call for action

Educational Objectives
- Understand the scope and implementation timeline of the new EU Health Technology Assessment Regulation (HTAR) effective from January 2025.
- Explore how the HTAR will affect national HTA bodies, with a specific case study from Belgium.
- Examine the implications of HTAR on nuclear medicine applications, including radioligand therapy.
- Engage in a multidisciplinary discussion on aligning nuclear medicine innovation with evolving European policy and regulatory frameworks.

Summary

This symposium will explore the growing importance of Health Technology Assessment (HTA) in nuclear medicine in light of the new EU HTA Regulation (HTAR), which enters into force in January 2025. Through expert presentations and a panel discussion, the session will provide insight into the regulation's expected impact on national HTA bodies, the role of patient advocacy, and its implications for emerging technologies such as radioligand therapy. The session aims to equip participants with a clearer understanding of how the HTAR will influence innovation, evaluation, and access to nuclear medicine technologies across Europe.

Key Words

Health Technology; HTA; Cost-effectiveness; Policy; PRAC; European Commission; EU; Nuclear Medicine; Radiopharmaceuticals